Amgen (NASDAQ:AMGN) Shares Purchased by Rep. David Taylor

Representative David Taylor (Republican-Ohio) recently bought shares of Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on October 1st, the Representative disclosed that they had bought between $1,001 and $15,000 in Amgen stock on September 22nd. The trade occurred in the Representative’s “DAVID TAYLOR TRUST > SARDINIA READY MIX 401(K) – DAVE” account.

Representative David Taylor also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Marathon Petroleum (NYSE:MPC) on 9/22/2026.
• Purchased $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/22/2026.
• Purchased $1,001 – $15,000 in shares of Installed Building Products (NYSE:IBP) on 9/8/2026.
• Purchased $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 9/8/2026.
• Sold $1,001 – $15,000 in shares of Amgen (NASDAQ:AMGN) on 8/26/2026.
• Sold $1,001 – $15,000 in shares of Vertex Pharmaceuticals (NASDAQ:VRTX) on 8/26/2026.
• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of Fifth Third Bancorp (NASDAQ:FITB) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of American Electric Power (NASDAQ:AEP) on 8/26/2026.

Amgen Trading Down 1.0%

Shares of AMGN opened at $403.04 on Friday. The stock has a fifty day moving average of $410.72 and a two-hundred day moving average of $370.33. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. The company has a market capitalization of $217.90 billion, a PE ratio of 25.05, a price-to-earnings-growth ratio of 2.94 and a beta of 0.41. Amgen Inc. has a fifty-two week low of $288.00 and a fifty-two week high of $447.03.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.62 by $0.67. The business had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The business’s revenue was up 9.5% on a year-over-year basis. During the same quarter last year, the firm earned $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, analysts forecast that Amgen Inc. will post 22.94 EPS for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were issued a $2.52 dividend. The ex-dividend date was Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.5%. Amgen’s payout ratio is 62.65%.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,252 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the transaction, the senior vice president directly owned 6,404 shares of the company’s stock, valued at $2,666,817.72. This represents a 16.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Nancy Grygiel sold 2,970 shares of the firm’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the sale, the senior vice president owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 6,222 shares of company stock worth $2,540,926 in the last ninety days. 0.85% of the stock is currently owned by insiders.

Institutional Trading of Amgen

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Miller Global Investments LLC boosted its holdings in Amgen by 111.4% in the 3rd quarter. Miller Global Investments LLC now owns 501 shares of the medical research company’s stock worth $211,000 after acquiring an additional 264 shares during the period. First Citizens Financial Corp acquired a new position in shares of Amgen during the third quarter worth $203,000. Polaris Financial Partners purchased a new position in shares of Amgen in the third quarter valued at $53,000. Planning Strategies Inc. boosted its stake in shares of Amgen by 29.6% in the third quarter. Planning Strategies Inc. now owns 206 shares of the medical research company’s stock valued at $87,000 after purchasing an additional 47 shares during the period. Finally, Private Client Services LLC acquired a new stake in Amgen during the 3rd quarter valued at $208,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on AMGN shares. Canaccord Genuity Group lifted their price target on Amgen from $366.00 to $384.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. Mizuho raised their target price on shares of Amgen from $303.00 to $352.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 18th. Truist Financial boosted their target price on shares of Amgen from $340.00 to $362.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. Weiss Ratings raised shares of Amgen from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, August 6th. Finally, The Goldman Sachs Group set a $389.00 price target on shares of Amgen in a research note on Friday, June 5th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $385.25.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio’s 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Taylor (Republican Party) ran for election to the U.S. House to represent Ohio’s 2nd Congressional District. He won in the general election on November 5, 2024.

David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor’s career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.